MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in ...

MDM2, on the other hand, is one of the most frequently studied oncogenes and is an excellent target for cancer therapy, based on its p53-dependent and p53-independent oncogenic activities in ...

ARF increases p53 levels by sequestering MDM2, which facilitates the degradation and inactivation of p53. p53 has both transactivation and transrepression activity, and so controls the ...

Covalent modification of the oncogene product Mdm2 by the ubiquitin-related protein SUMO1 protects it from ubiquitination and enhances its E3 ligase activity towards p53 in vitro. Disappearance of ...

Wild-type p53 is often engaged in response to cellular damage, where it acts to regulate genes that promote cell-cycle arrest, apoptosis, senescence, differentiation, and autophagy (Figure 1). In ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective ...